Rapamycin in aging and disease: maximizing efficacy while minimizing side effects
Rapamycin in aging and disease: maximizing efficacy while minimizing side effects
复制标题
DOI：
10.18632/oncotarget.10381
复制
发表时间：
2016-07-19
期刊：
影响因子：
--
通讯作者：
Kaeberlein, Matt
中科院分区：
文献类型：
--
作者：
Johnson, Simon C.;Kaeberlein, Matt
实验老年科学已经确定雷帕霉素是促进哺乳动物健康衰老和长寿的首选药物。随着多项独立研究成功地再现了雷帕霉素的寿命和健康促进作用，焦点已经转移到可能的翻译用途上。虽然是一种有前途的化合物，但雷帕霉素的临床使用受到与药物相关的副作用的限制。旨在确定最佳剂量方案、给药途径和制剂的研究将使益处最大化，同时减少副作用。
Experimental geroscience has identified rapamycin as a top candidate for promoting healthy aging and longevity in mammals. As multiple independent studies have successfully reproduced the lifespan and healthspan promoting effects of rapamycin, the focus has shifted to possible translational use. While a promising compound, clinical use of rapamycin is limited by concerns of side effects associated with the drug. Studies aimed at defining optimal dosage regimen, delivery route, and formulation will allow for benefits to be maximized while reducing side effects.